Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Meenakshi Goyal-Khemka"'
Autor:
Sharada A. Sarnaik, Ofelia A. Alvarez, William Owen, Murtadha Al-Khabori, Ashok Raj, Thomas Moulton, Bruce A. Barton, Charles T. Quinn, Suzie A. Noronha, Beng Fuh, Connie M. Piccone, Mark T. Gladwin, Philip Maes, Jennifer Keates-Baleeiro, Ed Parsley, Emad Salman, Nirmish Shah, Cameron K. Tebbi, Lewis L. Hsu, Abdulkareem Al-Momen, Kamar Godder, Yasser Wali, Jason M. Fixler, Claudia R. Morris, Yurdanur Kilinç, Christophe F. Chantrain, Suvankar Majumdar, Natalie L. Kamberos, Elena Cela de Julián, L. Vandy Black, Meenakshi Goyal-Khemka, Rebecca T. Gorney, Julie Kanter, Courtney D. Thornburg, Alex George, Zeynep Karakas, Betty S. Pace, Clarisse Lopes De Castro Lobo, Debra E. Cohen, Tammuella Singleton, Alexis A. Thompson, Clifford M. Takemoto, Joseph L. Lasky, Miguel R. Abboud, India Sisler, Rachelle Nuss, Shari S. Kronsberg, Claire S. Padgett, Adlette Inati, James F. Casella, Marty Emanuele, Richard A. Drachtman, Gregory J. Kato, Anne Schaefer, Anne M. Marsh
Publikováno v:
JAMA : the journal of the American Medical Association
Key PointsQuestionCan poloxamer 188, an agent that is reported to reduce blood viscosity and cell-cell interactions, effectively reduce the duration of vaso-occlusive episodes (painful crises) in hospitalized patients with sickle cell disease? Findin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e84aea32135688abaf3dfc1b204648c
https://doi.org/10.1001/jama.2021.3414
https://doi.org/10.1001/jama.2021.3414
Autor:
Lori Wagner, Vinay Vaidya, Kelli Fischbeck, Steve McCalley, Esteban Gomez, Brooke Cook, Joanna L. Gendreau, Meenakshi Goyal-Khemka, Christine M. Knoll, Sanjay J. Shah
Publikováno v:
Blood. 134:3384-3384
Background: Stroke, a feared and common complication of sickle cell anemia can be prevented by early recognition of at-risk individuals using annual screening transcranial Doppler ultrasound (TCD) and subsequent treatment with chronic transfusion the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ca20e1ddebe541b3248b3f289f4d613
https://doi.org/10.1182/blood-2019-128846
https://doi.org/10.1182/blood-2019-128846
Autor:
Lori Wagner, Esteban Gomez, Meenakshi Goyal-Khemka, Kelli Fischbeck, Sanjay J. Shah, Christine M. Knoll, Steve McCalley, Kyle Hickman, Vinay Vaidya, Brooke Cook, Joanna L. Gendreau
Publikováno v:
Blood. 134:2288-2288
Background: Hydroxyurea (HU) is an imperative disease-modifying agent in the treatment of sickle cell anemia (SCA). Over the past 30 years, numerous clinical trials have demonstrated both safety and efficacy of this medication in prevention of acute
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::258834628bc9fb36f034441689a808cf
https://doi.org/10.1182/blood-2019-127770
https://doi.org/10.1182/blood-2019-127770